65 results
Vasopressors Table 
Rough properties by Target Receptor, Heart Rate/Inotropy, Systemic Vascular Resistance, Cardiac Output, Blood Pressure,
Blood Pressure, Pulmonary ... Dobutamine 2-20 mcg ... Epinephrine 0-20 mcg ... Properties #Table #Pharmacology ... #Effect #Management
Asthma Medications and Mechanism of Action

#Asthma #Medications #Drugs #Pulmonary #Pharmacology #Management #Treatment
Medications #Drugs #Pulmonary ... #Pharmacology # ... Management #Treatment
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Prostanoid prescribing and management in Pulmonary Arterial Hypertension (PAH)
Oral Prostanoids:
 - Selexipag
 - Treprostinil
Inhaled Prostanoids
 -
prescribing and management ... in Pulmonary Arterial ... #prescribing #Pulmonary ... Hypertension #PAH #Management ... Algorithm #treatment #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
REBEL Review 74: Push-Dose Epinephrine 

9 mL Saline + 1 mL Epi (100mcq/mL) = Epinephrine 10mcg/mL
Epinephrine 9 mL ... Saline + 1 mL Epi ... 10mcg/mL 0.5 ... #criticalcare #management ... #pharmacology
IDSA Aspergillosis Treatment
 • Invasive pulmonary aspergillosis (IPA)
 • CNS aspergillosis
 • Cardiac Aspergillus infection
 •
Treatment • Invasive pulmonary ... Aspergillosis #Treatment #management ... #pharmacology #
Vasopressors and Inotropes - Pharmacology Summary
Vasopressors
Phenylephrine (alpha-1)
 • Increases BP, SVR
 • Risk of reflex bradycardia
and Inotropes - Pharmacology ... mild alpha (5-10 mcg ... CO • a (>10 mcg ... Vasopressors #Inotropes #Pharmacology ... #Summary #management
Choice of anticoagulant for treatment of pulmonary embolism
 • Malignancy - LMWH
 • To avoid parenteral
for treatment of pulmonary ... clearance <30 mL ... anticoagulation #pharmacology
Management of interstitial lung disease (ILD)-associated with systemic sclerosis (SSc)

Therapeutic indication: absolute decline in FVC >10%
Management of interstitial ... >10% (or >200 mL ... DLCO >15% (or 3 mL ... systemicsclerosis #SSc #pulmonary ... #indications #management